Beyond post-marketing research and MedWatch: Long-term studies of drug risks
Author:
Open Access
- 1 October 2007
- journal article
- other
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 1, 1-5
Abstract
Beyond post-marketing research and MedWatch: Long-term studies of drug risks David B ResnikNational Institute of EnvironmentalHealth Sciences (NIEHS)/National Institutes of Health (NIH) Critics of the drug safety system have discussed many different potential reforms, ranging from mandatory registration of clinical trials to increasing the power of regulatory agencies, but few have discussed one of the most important ways of enhancing safety: increasing the number of long-term studies of medications. Long-term studies of the risks and benefits of drugs can provide useful information for regulators, healthcare professionals, and patients. Government funding agencies should lead the effort to conduct long-term studies of drugs, but private companies should also be required to lend financial support. Because cost-effectiveness is likely to be an important consideration in conducting this research, funding agencies should focus, at first, on drugs that are used to treat common, chronic conditions.Keywords: drug safety, FDA, post-marketing studies, MedWatch, long-term studiesKeywords
This publication has 10 references indexed in Scilit:
- Challenges in Using Observational Studies to Evaluate Adverse Effects of TreatmentNew England Journal of Medicine, 2007
- Class of Antiretroviral Drugs and the Risk of Myocardial InfarctionNew England Journal of Medicine, 2007
- Drug Safety Reform at the FDA — Pendulum Swing or Systematic Improvement?New England Journal of Medicine, 2007
- Paying for Drug Approvals — Who's Using Whom?New England Journal of Medicine, 2007
- The Price of Truth2007
- How the US Drug Safety System Should Be ChangedJAMA, 2006
- Safety in Numbers — Monitoring Risk in Approved DrugsNew England Journal of Medicine, 2005
- Gaps in the Safety NetScience, 2005
- Postmarketing Surveillance—Lack of Vigilance, Lack of TrustJAMA, 2004
- Setting Biomedical Research Priorities: Justice, Science, and Public ParticipationKennedy Institute of Ethics Journal, 2001